000			04414cam a22004094a 4500
999			_c3842 _d3842
001			15794132
003			SUN
005			20180808155751.0
008			090625s2009 nyua b 001 0 eng
010			_a 2009026399
015			_aGBA970172 _2bnb
016	7		_a101509194 _2DNLM
016	7		_a015327476 _2Uk
020			_a9781607412557 (hardcover)
020			_a1607412551 (hardcover)
035			_a(OCoLC)ocn368045867
040			_aDNLM/DLC _cSUNLIB _dYDX _dNLM _dBTCTA _dUKM _dYDXCP _dCDX _dUBY _dDLC
042			_apcc
050	0	0	_aRC271.C5 _bD778 2009
060	0	0	_a2009 M-167
060	1	0	_aQZ 267 _bD79395 2009
082	0	0	_a616.994061/ _222 _bVER
245	0	0	_aDrug resistant neoplasms / _cEthan G. Verrite, editor.
260			_aNew York : _bNova Science Publishers, _cc2009.
300			_axiv, 254 p. : _bill. (some col.) ; _c27 cm.
490	1		_aCancer etiology, diagnosis and treatments series
504			_aIncludes bibliographical references and index.
505	0		_aTherapeutic implications of the intrinsic and acquired resistance of cancer stem/progenitor cells in inefficacy of current cancer treatments and disease relapse / Murielle Mimeault and Surinder K. Batra -- Role of O6-methyl guanine-DNA methyl transferase and the effect of O6-benzylguanine in cancer chemotherapy / Jun Murakami ... [et al.] -- The role of tumoural micro-environment and its vasculature on chemotherapy drug resistance: the potential for it's modulation to achieve therapeutic gain / A. Weickhardt and M. Michael -- Inherent and microenvironment-mediated mechanisms of drug resistance / Malathy P.V Shekhar -- Studies on the mechanisms of acquired resistance to EGFR tyrosine kinase inhibitor gefitinib in NSCLC cell lines: evidence that ligand-induced endocytosis of EGFR via the early/late endocytic pathway is associated with gefitinib sensitivity of NSCLC cell line / Yukio Nishimura -- Mechanisms of resistance to EGF receptor-tyrosine kinase inhibitor in NSCLC cell lines: gefitinib sensitivity is closely correlated with ligand-induced endocytosis of phosphorylated EGF receptor / Yukio Nishimura, Kiyoko Yoshioka and Kazuyuki Itoh -- Targeting adverse features of hormone-resistant breast cancer / Stephen Hiscox ... [et al.] -- Systematic analysis of patterns of cross resistance between anticancer agents / Britta Stordal and Ross Davey -- Molecular structure and energy: clinical importance in drug resistant neoplasms / Viroj Wiwanitkit -- Treating drug resistant malignancy / Viroj Wiwanitkit -- Overcoming ovarian cancer drug resistance with phytochemicals and other compounds / Marion M. Chan and Dunne Fong -- New research communications on cancer drug resistance, assessment of cancer drug resistance with nuclear medicine images / Seigo Kinuya.
520			_a"One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100% effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumors, even those from the same tissue of origin. Frequently, resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common. The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anticancer drugs from cells. Studies on the mechanisms of cancer drug resistance have yielded important information about how to circumvent this resistance to improve cancer chemotherapy and its implications for pharmacokinetics of many commonly used drugs. This book presents new and important research in this field."--Publisher's description.
650		0	_aDrug resistance in cancer cells. _99526
650	1	2	_aDrug Resistance, Neoplasm. _99527
700	1		_aVerrite, Ethan G. _99528
830		0	_aCancer etiology, diagnosis, and treatments. _94031
906			_a7 _bcbc _corignew _d1 _eecip _f20 _gy-gencatlg
942			_2ddc _cBK